Valerie Su joined the T1D Fund in August 2024. Prior to joining the Fund, she worked at Sanofi as a Scientist, advancing early drug discovery programs in autoimmune disease across multiple modalities, including antibodies, small molecules, and NANOBODY® molecules. She also completed a six-month internal internship in External Innovation, where she evaluated the competitive landscape for transplant therapies and helped prioritize external opportunities aligned with Sanofi’s portfolio strategy.

Valerie earned her Ph.D. in Pharmacology from Yale University in the laboratory of David Calderwood, where she studied molecular regulators of integrin and cerebral cavernous malformation signaling pathways. She received her B.A. in Molecular and Cell Biology from the University of California, Berkeley.

Eric Shen is Chief of Staff at the T1D Fund, where he partners with the leadership team to translate strategy into operating plans and drive execution across fundraising, portfolio support, and internal operations. He leads day-to-day firm operations, governance implementation, and financial planning, coordinating across finance, legal, compliance, and external partners.

Prior to joining the Fund, Eric was the Director of Corporate Development & Operations at Kojin Therapeutics, where he led corporate development, investor relations, finance, and strategic planning in partnership with the C-suite. Earlier in his career, he held corporate development and operational roles at Pear Therapeutics and Ohana Biosciences (Flagship Pioneering), and helped grow Old Silver Venture Capital, a venture capital firm supporting early-stage investments across biotech and digital health.

Eric earned a B.A. in Biology with a minor in Business from Brandeis University.